Population Pharmacokinetics of Cycloserine and Pharmacokinetic/Pharmacodynamic Target Attainment in Multidrug-Resistant Tuberculosis Patients Dosed with Terizidone
Maxwell Chirehwa, Richard Court, Mariana de Kock, Lubbe Wiesner, Nihal de Vries, Joseph W. Harding, Tawanda Gumbo, Gary Maartens, Robin M. Warren, Paolo Denti, Helen McIlleron
Abstract
Cycloserine is a WHO group B drug for the treatment of multidrug-resistant tuberculosis (TB). Pharmacokinetic/pharmacodynamic data for cycloserine when dosed as terizidone are sparse. The aim of this analysis was to describe the population pharmacokinetics of cycloserine when administered as terizidone and predict the doses of terizidone attaining cycloserine exposures associated with efficacy. The plasma cycloserine level was measured 2 to 6 weeks after treatment initiation in patients hospitalized for second-line tuberculosis treatment.
Topics & Concepts
CycloserinePharmacokineticsPharmacodynamicsPharmacologyTuberculosisMedicinePopulationPathologyEnvironmental healthAntibiotics Pharmacokinetics and EfficacyTuberculosis Research and EpidemiologyPneumocystis jirovecii pneumonia detection and treatment